🧬 1. Monoclonal Antibodies: Foundation of Modern Oncology
Monoclonal antibodies (mAbs) continue to anchor the Anticancer Drugs Market. In 2025, global sales for cancer-specific mAbs are projected to be USD 92–105 billion, soaring toward nearly USD 577 billion by 2034, at a remarkable CAGR of ~18–19% . These biologics—including humanized (Trastuzumab, Bevacizumab)...